FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1596317595> ?p ?o ?g. }

• W1596317595 endingPage "20403" @default.
• W1596317595 startingPage "20396" @default.
• W1596317595 abstract "// Yihang Shen 1 , Yuan-Hao Lee 1 , Jayabal Panneerselvam 1 , Jun Zhang 2 , Lenora W. M. Loo 3 and Peiwen Fei 1 1 Program of Cancer Biology, University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, USA 2 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA 3 Program of Epidemiology, University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, USA Correspondence to: Peiwen Fei, email: // Keywords : Fanconi anemia genes, TCGA, the mutated FA pathway, tumorigenesis, cancer treatment Received : March 10, 2015 Accepted : April 22, 2015 Published : May 09, 2015 Abstract An extremely high cancer incidence and the hypersensitivity to DNA crosslinking agents associated with Fanconi Anemia (FA) have marked it to be a unique genetic model system to study human cancer etiology and treatment, which has emerged an intense area of investigation in cancer research. However, there is limited information about the relationship between the mutated FA pathway and the cancer development or/and treatment in patients without FA. Here we analyzed the mutation rates of the seventeen FA genes in 68 DNA sequence datasets. We found that the FA pathway is frequently mutated across a variety of human cancers, with a rate mostly in the range of 15 to 35 % in human lung, brain, bladder, ovarian, breast cancers, or others. Furthermore, we found a statistically significant correlation ( p < 0.05) between the mutated FA pathway and the development of human bladder cancer that we only further analyzed. Together, our study demonstrates a previously unknown fact that the mutated FA pathway frequently occurs during the development of non-FA human cancers, holding profound implications directly in advancing our understanding of human tumorigenesis as well as tumor sensitivity/resistance to crosslinking drug-relevant chemotherapy." @default.
• W1596317595 created "2016-06-24" @default.
• W1596317595 creator A5010197061 @default.
• W1596317595 creator A5032640001 @default.
• W1596317595 creator A5044097220 @default.
• W1596317595 creator A5044157771 @default.
• W1596317595 creator A5070055942 @default.
• W1596317595 creator A5071672663 @default.
• W1596317595 date "2015-05-09" @default.
• W1596317595 modified "2023-10-16" @default.
• W1596317595 title "Mutated Fanconi anemia pathway in non-Fanconi anemia cancers" @default.
• W1596317595 cites W1510933933 @default.
• W1596317595 cites W1523055419 @default.
• W1596317595 cites W1545225980 @default.
• W1596317595 cites W1598765244 @default.
• W1596317595 cites W1851780220 @default.
• W1596317595 cites W1929113708 @default.
• W1596317595 cites W1955477326 @default.
• W1596317595 cites W1966730768 @default.
• W1596317595 cites W1966900148 @default.
• W1596317595 cites W1973266695 @default.
• W1596317595 cites W1974545699 @default.
• W1596317595 cites W1978683051 @default.
• W1596317595 cites W1985889132 @default.
• W1596317595 cites W1986096893 @default.
• W1596317595 cites W1987871280 @default.
• W1596317595 cites W2011186822 @default.
• W1596317595 cites W2011291904 @default.
• W1596317595 cites W2015901442 @default.
• W1596317595 cites W2017329539 @default.
• W1596317595 cites W2018679721 @default.
• W1596317595 cites W2019078072 @default.
• W1596317595 cites W2019402498 @default.
• W1596317595 cites W2020064661 @default.
• W1596317595 cites W2023489614 @default.
• W1596317595 cites W2025967759 @default.
• W1596317595 cites W2027123734 @default.
• W1596317595 cites W2027966589 @default.
• W1596317595 cites W2033633647 @default.
• W1596317595 cites W2036124213 @default.
• W1596317595 cites W2036826205 @default.
• W1596317595 cites W2036868742 @default.
• W1596317595 cites W2042091701 @default.
• W1596317595 cites W2048446461 @default.
• W1596317595 cites W2049013265 @default.
• W1596317595 cites W2054367725 @default.
• W1596317595 cites W2055611673 @default.
• W1596317595 cites W2056695542 @default.
• W1596317595 cites W2063563776 @default.
• W1596317595 cites W2077677117 @default.
• W1596317595 cites W2082686135 @default.
• W1596317595 cites W2096726943 @default.
• W1596317595 cites W2102485452 @default.
• W1596317595 cites W2114843025 @default.
• W1596317595 cites W2124269410 @default.
• W1596317595 cites W2127808743 @default.
• W1596317595 cites W2137273906 @default.
• W1596317595 cites W2148579479 @default.
• W1596317595 cites W2149441684 @default.
• W1596317595 cites W2155831794 @default.
• W1596317595 cites W2159048953 @default.
• W1596317595 cites W2168885419 @default.
• W1596317595 cites W2171400810 @default.
• W1596317595 cites W2188391895 @default.
• W1596317595 cites W2281048538 @default.
• W1596317595 cites W2335374726 @default.
• W1596317595 cites W2402872615 @default.
• W1596317595 cites W2467891846 @default.
• W1596317595 doi "https://doi.org/10.18632/oncotarget.4056" @default.
• W1596317595 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4653013" @default.
• W1596317595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26015400" @default.
• W1596317595 hasPublicationYear "2015" @default.
• W1596317595 type Work @default.
• W1596317595 sameAs 1596317595 @default.
• W1596317595 citedByCount "22" @default.
• W1596317595 countsByYear W15963175952015 @default.
• W1596317595 countsByYear W15963175952016 @default.
• W1596317595 countsByYear W15963175952017 @default.
• W1596317595 countsByYear W15963175952018 @default.
• W1596317595 countsByYear W15963175952019 @default.
• W1596317595 countsByYear W15963175952020 @default.
• W1596317595 countsByYear W15963175952022 @default.
• W1596317595 crossrefType "journal-article" @default.
• W1596317595 hasAuthorship W1596317595A5010197061 @default.
• W1596317595 hasAuthorship W1596317595A5032640001 @default.
• W1596317595 hasAuthorship W1596317595A5044097220 @default.
• W1596317595 hasAuthorship W1596317595A5044157771 @default.
• W1596317595 hasAuthorship W1596317595A5070055942 @default.
• W1596317595 hasAuthorship W1596317595A5071672663 @default.
• W1596317595 hasBestOaLocation W15963175951 @default.
• W1596317595 hasConcept C104317684 @default.
• W1596317595 hasConcept C121608353 @default.
• W1596317595 hasConcept C126322002 @default.
• W1596317595 hasConcept C134935766 @default.
• W1596317595 hasConcept C143998085 @default.
• W1596317595 hasConcept C2776256026 @default.
• W1596317595 hasConcept C2778124228 @default.
• W1596317595 hasConcept C502942594 @default.

• next